An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
*For Eligibility information, look up the trial at NIH by clicking on the Study Number above.*
Other eligibility criteria may apply.
Other exclusion criteria may apply.